Brokerages expect Emergent Biosolutions, Inc. (NYSE:EBS) to report earnings per share (EPS) of $0.59 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Emergent Biosolutions’ earnings, with estimates ranging from $0.46 to $0.71. Emergent Biosolutions posted earnings per share of $0.74 during the same quarter last year, which suggests a negative year over year growth rate of 20.3%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Emergent Biosolutions will report full year earnings of $1.58 per share for the current year, with EPS estimates ranging from $1.49 to $1.72. For the next year, analysts forecast that the company will report earnings of $2.36 per share, with EPS estimates ranging from $1.84 to $2.70. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business had revenue of $149.43 million during the quarter, compared to analyst estimates of $124.55 million. During the same quarter last year, the firm earned $0.56 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year.

A number of equities research analysts have recently issued reports on EBS shares. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Wednesday, October 25th. Wells Fargo & Company reiterated an “outperform” rating and issued a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Finally, BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $46.00.

Emergent Biosolutions (NYSE:EBS) traded up $0.22 during mid-day trading on Friday, hitting $46.94. The stock had a trading volume of 318,465 shares, compared to its average volume of 347,259. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a fifty-two week low of $27.94 and a fifty-two week high of $47.37. The firm has a market capitalization of $1,910.81, a price-to-earnings ratio of 24.42, a P/E/G ratio of 1.33 and a beta of 1.24.

In related news, EVP Adam Havey sold 7,885 shares of the stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $39.50, for a total value of $311,457.50. Following the completion of the transaction, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,340,274.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Abdun-Nabi sold 20,000 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $45.99, for a total value of $919,800.00. Following the completion of the transaction, the chief executive officer now directly owns 224,134 shares of the company’s stock, valued at approximately $10,307,922.66. The disclosure for this sale can be found here. Insiders sold 280,989 shares of company stock valued at $11,700,343 in the last three months. 16.50% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of EBS. Riverhead Capital Management LLC boosted its holdings in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 587 shares during the last quarter. First Quadrant L P CA purchased a new position in Emergent Biosolutions in the third quarter valued at about $157,000. Meeder Asset Management Inc. boosted its holdings in Emergent Biosolutions by 94.7% in the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 2,302 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Emergent Biosolutions in the third quarter valued at about $191,000. 88.44% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “$0.59 Earnings Per Share Expected for Emergent Biosolutions, Inc. (EBS) This Quarter” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/0-59-earnings-per-share-expected-for-emergent-biosolutions-inc-ebs-this-quarter/1775015.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.